Noah Merin, MD
Hematology · West Hollywood, CANPI 1659547487
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $88,359 of the $134,270 with a category attached, or 65.8%. It is spread thinly across 33 manufacturers, the largest accounting for just 11.3%. Reporting peaked in 2024 at $39,960 and has fallen 83.1% since, to $6,755 in 2025.
Across 194 payments — averaging $692.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$15K
- ADC Therapeutics America, Inc.$14K
- Roche TCRC, Inc.$14K
- Servier Pharmaceuticals LLC$13K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- Genentech USA, Inc.$9K
- plus $59K from 27 others
Across 13 payments — averaging $128,306 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$758K
- Amgen$710K
- AstraZeneca$167K
- Gilead$33K
What the payments were for
- Consulting fees$88,35966%
- Speaking & faculty fees$13,42010%
- Travel & lodging$22,18717%
- Food & beverage$10,1308%
- Education$1750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 22 | $15,184 |
| ADC Therapeutics America, Inc. | 19 | $14,216 |
| Roche TCRC, Inc. | 3 | $13,660 |
| Servier Pharmaceuticals LLC | 15 | $12,585 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $10,436 |
| Genentech USA, Inc. | 8 | $9,294 |
| Incyte Corporation | 11 | $9,259 |
| Acceleron Pharma, Inc. | 6 | $8,903 |
| Amgen | 9 | $8,845 |
| Ipsen Biopharmaceuticals, Inc | 3 | $6,020 |
| AstraZeneca(2 entities) | 17 | $4,673 |
| Agios Pharmaceuticals, Inc. | 12 | $4,115 |
| Adaptive Biotechnologies Corporation | 3 | $2,976 |
| Johnson & Johnson | 16 | $2,537 |
| Stemline Therapeutics Inc. | 1 | $2,170 |
| Beigene USA, Inc. | 2 | $1,970 |
| Dova Pharmaceuticals | 2 | $1,718 |
| Epizyme, Inc. | 2 | $1,350 |
| Bayer | 1 | $1,125 |
| Jazz Pharmaceuticals Inc. | 4 | $477 |
| Novartis | 6 | $476 |
| Seagen Inc. | 4 | $452 |
| Bristol Myers Squibb | 3 | $345 |
| Astellas Pharma US Inc | 2 | $244 |
| E.r. Squibb & Sons, L.L.C. | 2 | $243 |
| Karyopharm Therapeutics Inc. | 5 | $235 |
| Sanofi | 1 | $154 |
| GSK | 1 | $125 |
| Pfizer | 1 | $122 |
| TG Therapeutics, Inc. | 1 | $120 |
| Rigel Pharmaceuticals, Inc. | 1 | $107 |
| AbbVie | 1 | $101 |
| Verastem, Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$134,270 in reported general payments places this provider in the 85th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IclusigPonatinib Hcl | 36 | $683,754 |
| SprycelDasatinib | 36 | $403,839 |
| JakafiRuxolitinib Phosphate | 18 | $307,793 |
| RezurockBelumosudil Mesylate | 12 | $216,932 |
| ImbruvicaIbrutinib | 12 | $102,335 |
| VenclextaVenetoclax | 17 | $23,220 |
| Voriconazole | 27 | $12,570 |
| ValacyclovirValacyclovir Hcl | 41 | $2,083 |
| Acyclovir | 25 | $483 |
| Levofloxacin | 25 | $400 |
| Prednisone | 11 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $10,436 | $683,75436 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $243 | $403,83936 claims |
| Incyte CorporationJakafi | $9,259 | $307,79318 claims |
| AbbVieVenclexta | $101 | $23,22017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 178 hematology providers in California.
Other hematology in West Hollywood
- Everett MeyerStanford$2.1M
- Doris QuonLos Angeles$1.5M
- Amrita KrishnanDuarte$671K
- Ilene WeitzLos Angeles$631K
- Vinod PullarkatDuarte$576K
- Hope RugoSan Francisco$537K
- Alexey DanilovDuarte$407K
- Caroline PiatekLos Angeles$391K
- Deepu MadduriStanford$348K
- Tycel PhillipsDuarte$348K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.